Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as unlimited liability partner, has made an additional investment in Sias Inc. (Sakyo-ku, Kyoto; Representative Director: Yasumichi Toh), which promotes research and development of regenerative T-cell therapy using iPS cell technology developed at Kyoto University.

Outline of this investment
The funds raised will be used by Sias to fund pre-clinical trials and the development of a new pipeline. In addition to strengthening research and development, collaborating with partner companies, and discussing with regulatory authorities, Sias intends to pursue aggressive business development, aiming for the practical application of treatments for cancer and infectious diseases, and the clinical application of regenerative T-cell therapies using iPS cell technology.

Kyoto iCAP decided to make this investment in recognition of the challenge and social significance of Sias' efforts to deliver regenerative T-cell therapy, which could become an important technology for advanced cancer immunotherapy using Kyoto University's iPS cell technology, to patients as soon as possible. Kyoto iCAP, together with D3 Bio-Healthcare Fund No. 1 Investment Limited Partnership (unlimited liability partner: D3 LLC, Representative Partner and CEO Tomoya Nagata), has subscribed approximately 200 million yen of the approximately 300 million yen third-party allocation of new shares in the Series A3 round as of October 29.

Outline of Sias Corporation

Establishment	August 24, 2015
Business	Development of therapies for cancer and other diseases using regenerated T cells
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Yasumichi Todo (CEO/CTO), Ryosuke Gonotsubo (COO/CFO)